Omalizumab-based therapy in normocomplementemic urticarial vasculitis: a retrospective case series of 18 patients
Anais Brasileiros de Dermatologia · 2026
DOI: 10.1016/j.abd.2026.501424 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anais Brasileiros de Dermatologia, 2026. Verfasst von Melek Aslan Kayiran und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey. Hauptthemen laut MEDLINE: Omalizumab, Urticaria, Anti-Allergic Agents, Vasculitis. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Istanbul Medeniyet University.
Abstract (Originalsprache)
Background
Urticarial Vasculitis (UV) is a rare immune-complex-mediated vasculitis characterized by urticarial lesions lasting ≥24 hours and small-vessel inflammation. Management is challenging, and evidence for omalizumab, an anti-IgE monoclonal antibody, remains limited.
Objectives
To evaluate clinical and laboratory outcomes and safety of omalizumab-based therapy in patients with clinicopathologically diagnosed normocomplementemic UV.
Methods
This retrospective study included 18 patients with clinicopathologically diagnosed normocomplementemic UV treated with omalizumab. Demographics, disease duration, comorbidities, and laboratory parameters (C-Reactive Protein [CRP], Erythrocyte Sedimentation Rate [ESR], total Immunoglobulin E [IgE]) and Urticaria Activity Score over 7 days (UAS7) were assessed before and after treatment.
Results
Eighteen patients (14 females, 4 males) with a mean age of 47.3 ± 16.8 years were included. Mean disease duration was 15.8 ± 10.8 months, and mean omalizumab treatment duration was 14.8 ± 12.0 months. Mean UAS7 decreased significantly from 25.3 ± 7.7 to 1.2 ± 3.4 (p < 0.001). CRP also decreased significantly (10.7 ± 17.2 to 3.6 ± 3.3 mg/L; p = 0.002), while the reduction in ESR was not significant (18.2 ± 26.5 to 10.9 ± 7.8 mm/h; p = 0.124). Total IgE increased after treatment (451.6 ± 1075.5 to 496.4 ± 621.2 IU/mL; p = 0.010). Complete remission occurred in 17 patients (94%). No treatment-related adverse events were observed. Study limitations Limitations include retrospective design, small sample size, lack of a control group, and concomitant therapies.
Conclusions
Omalizumab was associated with marked clinical improvement and favorable safety in normocomplementemic UV, supporting a potential role for IgE-mediated mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Faculty of Medicine, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey.
- Department of Dermatology, Faculty of Medicine, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey. Electronic address: kubrakdemir.11@gmail.com.
- Department of Pathology, Faculty of Medicine, Goztepe Training and Research Hospital, Istanbul Medeniyet University, Istanbul, Turkey.
Förderung
- Istanbul Medeniyet University
Zitieren
APA
Kayiran, M. A., Yucel, K. A., Simsek, B. C., & Gurel, M. S. (2026). Omalizumab-based therapy in normocomplementemic urticarial vasculitis: a retrospective case series of 18 patients. Anais Brasileiros de Dermatologia. https://doi.org/10.1016/j.abd.2026.501424
Vancouver
Kayiran MA, Yucel KA, Simsek BC, Gurel MS. Omalizumab-based therapy in normocomplementemic urticarial vasculitis: a retrospective case series of 18 patients. Anais Brasileiros de Dermatologia. 2026. doi:10.1016/j.abd.2026.501424
BibTeX
@article{Kayiran2026,
author = {Kayiran, Melek Aslan and Yucel, Kubra Akdemir and Simsek, Bengu Cobanoglu and Gurel, Mehmet Salih},
title = {Omalizumab-based therapy in normocomplementemic urticarial vasculitis: a retrospective case series of 18 patients},
journal = {Anais Brasileiros de Dermatologia},
year = {2026},
doi = {10.1016/j.abd.2026.501424}
}
EUVIMED